Trial · NCT07440563
Auricular Vagus Nerve Stimulation Combined With Rehabilitation in Parkinson's Disease
NCT07440563, Not applicable, Enrolling by invitation, Gazi University
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Auricular Vagus Nerve Stimulation Combined With Rehabilitation in Parkinson's Disease. Trials, record NCT07440563. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07440563
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Auricular Vagus Nerve Stimulation Combined With Rehabilitation in Parkinson's Disease
- NCT number
- NCT07440563
- Status
- Enrolling by invitation
- Phases
- Not applicable
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Gazi University
- Conditions
- PARKINSON DISEASE (Disorder)
- Interventions
- Neurological Physiotherapy and Rehabilitation Combined with Active Vagus Nerve Stimua, Neurological Physiotherapy and Rehabilitation Combined with Sham Vagus Nerve Stimua
- First posted
- 2026-02-27
- Last updated
- 2026-03-05
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Movement Disorders Society-Unified Parkinson's Disease Rating Scale | twice: once on the initial assessment day and once after the 3-week program. | The Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) was used to assess motor and non-motor symptom severity in individuals with Parkinson's disease. The MDS-UPDRS is a validated, comprehensive clinical rating scale consisting of four parts: non-motor experiences of daily living (Part I), motor experiences of daily living (Part II), motor examination (Part III), and motor complications (Part IV). Higher scores indicate greater symptom severity. The scale has demonstrated excellent reliability, validity, and sensitivity to change in clinical trials and is widely recommended as a primary outcome measure in Parkinson's disease research. |
| Primary | Postural Stability | twice: once on the initial assessment day and once after the 3-week program. | The force platform, considered the gold standard for the quantitative assessment of postural stability, is a valid and reliable method that enables objective evaluation of balance. In this study, postural stability during quiet standing will be assessed using a force platform. Participants will stand on the platform in a standardized foot position, with their arms at their sides and their gaze fixed forward. Measurements will be performed under eyes-open and eyes-closed conditions. For each condition, trials of fixed duration will be recorded, and center of pressure (CoP) parameter will be calculated. Higher CoP value will indicate reduced postural stability. Measurements will be repeated according to a standardized protocol, and the average values will be used for analysis. |
| Primary | Spatiotemporal Gait Parameters | twice: once on the initial assessment day and once after the 3-week program. | Spatiotemporal gait characteristics will be evaluated using a gait analysis system. Participants will walk across the walkway six times at their self-selected comfortable speed. Temporal and spatial parameters (step length, stride length, step time, stride time, double support time) of gait, as well as variability measures, will be calculated. |
| Primary | Functional Walking Capacity | twice: once on the initial assessment day and once after the 3-week program. | Functional walking capacity will be assessed using the 6-Minute Walk Test (6MWT). Participants will be instructed to walk as far as possible within six minutes along a standardized walkway. The total distance covered will be recorded in meters. In individuals with Parkinson's disease, the minimal clinically important difference has been reported as 82 meters. |
| Secondary | Berg Balance Sclae | twice: once on the initial assessment day and once after the 3-week program. | Functional balance will be assessed using the Berg Balance Scale (BBS), a widely used and validated clinical scale for the evaluation of balance performance in individuals with neurological conditions. The BBS consists of 14 functional tasks, including sitting, standing, transfers, reaching, turning, and single-leg stance. Each item is scored on a 5-point ordinal scale ranging from 0 to 4, with a maximum total score of 56 points. Higher scores indicate better balance performance. The BBS has demonstrated high reliability, validity, and sensitivity to change in individuals with Parkinson's disease and other neurological populations. |
| Secondary | Activities-specific Balance Confidence Scale | twice: once on the initial assessment day and once after the 3-week program. | Balance confidence will be assessed using the Activities-specific Balance Confidence Scale (ABC). The ABC is a self-reported questionnaire designed to evaluate an individual's confidence in maintaining balance during various daily activities. It consists of 16 items, each scored from 0% (no confidence) to 100% (complete confidence). The overall score is calculated as the average of all item scores, with higher values indicating greater balance confidence. The ABC has demonstrated good reliability, validity, and responsiveness in individuals with Parkinson's disease and other neurological populations. |
| Secondary | Functional Mobility | twice: once on the initial assessment day and once after the 3-week program. | Functional mobility will be assessed using the Timed Up and Go Test (TUG). In this test, participants are instructed to stand up from a chair on the command "go," walk 3 meters, turn around, walk back, and sit down again. The test is performed on a flat, unobstructed 3-meter walkway. Timing begins at the command "go" and stops when the participant sits back in the chair. A chair with armrests will be used (seat height: 50 cm, seat depth: 47 cm, seat width: 50 cm, armrest height: 65 cm). One practice trial will be performed, followed by two recorded trials, and the final measurement will be used for analysis. |
| Secondary | Trail Making Test | twice: once on the initial assessment day and once after the 3-week program. | The Trail Making Test (TMT) is used to assess executive functions, task-switching ability, attention, visual scanning speed, visuomotor processing, planning, organization, abstract thinking, and response inhibition. The test consists of two parts: Part A (TMT-A) and Part B (TMT-B). In Part A, participants are asked to connect numbered circles in sequential order from 1 to 25, and the completion time is recorded. In Part B, participants are required to alternate between numbers and letters in sequence (e.g., 1-A-2-B-3-C), and the completion time is recorded. |
| Secondary | Stroop Test | twice: once on the initial assessment day and once after the 3-week program. | The Stroop Test is a cognitive assessment that evaluates executive functions, particularly selective attention, cognitive flexibility, and the ability to inhibit automatic responses under interference conditions. In this study, the Stroop Test-Basic Sciences Research Group Form (ST-BSRG) will be used. This form is a combined version of the original Stroop Test and the Victoria version. The test is administered in five sections using four different cards. Each card contains six rows, with each row consisting of four items arranged in sequence. The completion time and errors are recorded for analysis. |
| Secondary | Quality of Life Assessment | twice: once on the initial assessment day and once after the 3-week program. | Quality of life will be evaluated using the Parkinson's Disease Questionnaire-8 (PDQ-8). The PDQ-8 is a short-form, disease-specific questionnaire that assesses the impact of Parkinson's disease on quality of life. The items evaluate the individual's experiences over the previous month and are scored on a scale from 0 (never) to 4 (always). The total score is converted to a 0-100 scale, with higher scores indicating poorer quality of life. The Turkish version of the PDQ-8 has been shown to be valid and reliable, with excellent test-retest reliability (ICC = 0.97) as reported by Kahraman and colleagues. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Task Switching Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07440563
GET https://conductscience.org/api/trials/v1/NCT07440563/registered